Download video

Obinutuzumab plus ibrutinib and venetoclax treatment continues to yield high response rates in CLL

850 views

VJHemOnc – Video Journal of Hematology & HemOnc

2 years ago

Obinutuzumab plus ibrutinib and venetoclax treatment continues to yield high response rates in CLL

Obinutuzumab plus ibrutinib and venetoclax treatment continues to yield high response rates in CLL

Ibrutinib plus venetoclax followed by MRD-guided ibrutinib plus obinutuzumab in first line CLL
4:36
Ibrutinib plus venetoclax followed by MRD-guided ibrutinib plus obinutuzumab in first line CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
The triple combination of venetoclax-ibrutinib-obinutuzumab prolongs PFS compared to venetoclax-...
4:39
The triple combination of venetoclax-ibrutinib-obinutuzumab prolongs PFS compared to venetoclax-...
by ecancer
Ibrutinib, Venetoclax \& Obinutuzumab to Treat Chronic Lymphocytic Leukemia (CLL) - Dr. Woyach
15:16
Ibrutinib, Venetoclax \& Obinutuzumab to Treat Chronic Lymphocytic Leukemia (CLL) - Dr. Woyach
by CLL Society
Phase II study of fixed-duration obinutuzumab, ibrutinib \& venetoclax in elderly patients with RT
2:03
Phase II study of fixed-duration obinutuzumab, ibrutinib \& venetoclax in elderly patients with RT
by VJHemOnc – Video Journal of Hematology \& HemOnc
Obinutuzumab plus ibrutinib and venetoclax treatment continues to yield high response rates in CLL
1:36
Obinutuzumab plus ibrutinib and venetoclax treatment continues to yield high response rates in CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
CLL2-GiVe trial: ibrutinib, venetoclax and obinutuzumab in patients with TP53-mutated CLL
1:36
CLL2-GiVe trial: ibrutinib, venetoclax and obinutuzumab in patients with TP53-mutated CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
The CLL2-BZAG trial: MRD-guided zanubrutinib, venetoclax, and obinutuzumab in R\/R CLL
1:11
The CLL2-BZAG trial: MRD-guided zanubrutinib, venetoclax, and obinutuzumab in R\/R CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
3-year follow-up of obinutuzumab, ibrutinib and venetoclax for CLL
6:34
3-year follow-up of obinutuzumab, ibrutinib and venetoclax for CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
Four-year follow-up from a Phase II study of obinutuzumab, ibrutinib, and venetoclax in CLL
2:43
Four-year follow-up from a Phase II study of obinutuzumab, ibrutinib, and venetoclax in CLL
by VJHemOnc – Video Journal of Hematology \& HemOnc
Acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-l...
2:57
Acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-l...
by ecancer
A Phase II single-arm study of obinutuzumab plus ibrutinib as frontline treatment for FL and MZL
1:02
A Phase II single-arm study of obinutuzumab plus ibrutinib as frontline treatment for FL and MZL
by VJHemOnc – Video Journal of Hematology \& HemOnc
Obinutuzumab, ibrutinib, and venetoclax in high-risk CLL: the CLL2-GIVe and CLL13 trials
2:00
Obinutuzumab, ibrutinib, and venetoclax in high-risk CLL: the CLL2-GIVe and CLL13 trials
by VJHemOnc – Video Journal of Hematology \& HemOnc
Novel agent combinations for CLL: ibrutinib, venetoclax, obinutuzumab and zanubrutinib
1:46
Novel agent combinations for CLL: ibrutinib, venetoclax, obinutuzumab and zanubrutinib
by VJHemOnc – Video Journal of Hematology \& HemOnc
What Is the Best Strategy for Frontline Venetoclax Plus Obinutuzumab in CLL?
0:37
What Is the Best Strategy for Frontline Venetoclax Plus Obinutuzumab in CLL?
by Blood Cancers Today
BruVenG trial: zanubrutinib and venetoclax, with obinutuzumab consolidation following MRD-positivity
3:15
BruVenG trial: zanubrutinib and venetoclax, with obinutuzumab consolidation following MRD-positivity
by VJHemOnc – Video Journal of Hematology \& HemOnc
Venetoclax Combined with Obinutuzumab for Untreated CLL (Chronic Lymphocytic Leukemia)
8:57
Venetoclax Combined with Obinutuzumab for Untreated CLL (Chronic Lymphocytic Leukemia)
by CLL Society
EHA22: TIME-LIMITED VENETOCLAX-OBINUTUZUMAB +\/- IBRUTINIB IS SUPERIOR TO CHEMOIMMUNOTHERAPY IN ...
10:20
EHA22: TIME-LIMITED VENETOCLAX-OBINUTUZUMAB +\/- IBRUTINIB IS SUPERIOR TO CHEMOIMMUNOTHERAPY IN ...
by Oncoletter
Dr. Rogers Discusses Obinutuzumab, Ibrutinib, and Venetoclax Combination in CLL
1:25
Dr. Rogers Discusses Obinutuzumab, Ibrutinib, and Venetoclax Combination in CLL
by OncLive
Dr. Abedin on the Role of Venetoclax Plus Obinutuzumab in CLL
1:01
Dr. Abedin on the Role of Venetoclax Plus Obinutuzumab in CLL
by OncLive